Johns Hopkins spinout Pearl Diagnostics raises $11.2M to bring infection screening to market

A Baltimore-based biotech startup raised over $11 million to take its product to the next stage of commercialization. Pearl Diagnostics just completed a Series A round to help bring its noninvasive fungal infection test to market after a recent Food and Drug Administration clearance. Many of the other big wins this month centered on supporting the state’s biotech work, too.